Table 1 Baseline characteristics of the study population

Age (years)

58.5 ± 9.8

58.7 ± 10.3

64.0 ± 8.7

61.9 ± 9.0

< 0.001

Women, n (%)

125(24.4)

144(29.6)

133(27.0)

177(34.5)

0.03

BMI (kg/m²)

26.5 ± 3.3

26.4 ± 3.3

25.8 ± 3.1

25.9 ± 3.2

< 0.001

Comorbidities, n (%)

Hypertension

383(74.8)

332(68.2)

374(75.9)

371(72.3)

0.034

Hyperlipidemia

427(83.4)

430(88.3)

387(78.5)

439(85.6)

< 0.001

Current smoker

163(31.8)

151(31)

119(24.1)

131(25.5)

0.011

Prior MI

69(13.5)

72(14.8)

101(20.5)

87(17)

0.017

Prior PCI

176(34.4)

160(32.9)

192(38.9)

187(36.5)

0.212

Prior stroke

32(6.3)

42(8.6)

52(10.5)

52(10.1)

0.068

HF

14(2.7)

20(4.1)

30(6.1)

34(6.6)

0.014

CKD

14(2.7)

22(4.5)

51(10.3)

34(6.6)

< 0.001

PAD

14(2.7)

18(3.7)

23(4.7)

18(3.5)

0.44

ACS type, n (%)

STEMI

19(3.7)

19(3.9)

18(3.7)

50(9.7)

< 0.001

NSTEMI

33(6.4)

34(7.0)

47(9.5)

68(13.3)

< 0.001

UAP

460(89.9)

434(89.1)

428(86.8)

397(77.0)

< 0.001

Procedure characteristics

Multivessel disease, n (%)

381(74.4)

363(74.5)

381(77.3)

397(77.4)

0.523

Left main lesion, n (%)

29(5.7)

37(7.6)

45(9.1)

31(6)

0.125

Bifurcation lesion, n (%)

67(13.1)

47(9.7)

45(9.1)

67(13.1)

0.18

Chronic total occlusion, n (%)

57(11.1)

64(13.1)

72(14.6)

63(12.3)

0.409

Stent number

1.6 ± 1.0

1.6 ± 0.9

1.6 ± 0.9

1.6 ± 0.9

0.623

Total stent length (mm)

30(20,48.5)

32(20,51)

32(20,51)

30(20,50)

0.761

Basic laboratory data

TLCs (×10/⁹L)

2.1 ± 1.1

2.2 ± 0.6

1.4 ± 0.4

1.5 ± 0.4

< 0.001

HGB (g/L)

145.3 ± 14.9

145.6 ± 15.3

135.1 ± 17.2

137.4 ± 16.7

< 0.001

Alb (g/L)

47.0 ± 2.9

46.4 ± 2.8

42.4 ± 3.0

41.8 ± 3.2

< 0.001

TG (mmol/L)

1.6(1.2,2.1)

1.7(1.3,2.4)

1.4(1.1,1.9)

1.5(1.1,2.2)

< 0.001

TC (mmol/L)

4.0 ± 1

4.3 ± 1.1

3.9 ± 0.9

4.2 ± 1.1

< 0.001

LDL-C (mmol/L)

2.1 ± 0.8

2.3 ± 0.9

2.1 ± 0.8

2.3 ± 0.9

< 0.001

HDL-C (mmol/L)

1.1 ± 0.3

1.0 ± 0.2

1.0 ± 0.3

1.0 ± 0.3

0.051

Glucose (mmol/L)

6.7(5.8,7.8)

8.6(6.9,11.2)

6.7(5.7,7.9)

9.0(6.9,12.3)

< 0.001

HbA1c (%)

6.4 ± 0.5

8.3 ± 1.0

6.4 ± 0.5

8.4 ± 1.1

< 0.001

CR (µmol/L)

75.9(66.0,88.1)

76.3(67.3,87.3)

77.8(66.6,90.8)

78.0(66.0,91.6)

0.03

eGFR (ml/min per 1.73 m²)

92.6(66.0,91.6)

92.2(76,102.0)

87.3(70.8,95.8)

86.6(70.9,98.2)

< 0.001

UA (µmol/L)

330.5 ± 83.4

330.5 ± 96.8

332.3 ± 97.4

319 ± 89.7

0.002

LVEF (%)

61.7 ± 6.8

60.9 ± 7.6

60.1 ± 8

59.1 ± 9

< 0.001

PNI

56.4(54.7,59.0)

56.7(54.9,59)

56.4(48.1,51.8)

50.1(47.6,51.6)

< 0.001

Pharmacotherapy, n (%)

Aspirin

503(98.2)

474(97.3)

484(98.2)

503(98.1)

0.729

Clopidogrel

318(62.1)

301(61.8)

335(68)

341(66.5)

0.1

Ticagrelor

197(38.5)

192(39.4)

161(32.7)

179(34.9)

0.095

Statin

511(99.8)

485(99.6)

491(99.6)

511(99.6)

0.925

ACEI/ARB

232(45.3)

186(38.2)

200(40.6)

218(42.5)

0.132

β-Blocker

357(69.7)

349(71.7)

317(64.3)

340(66.3)

0.057

CCB

196(38.3)

170(34.9)

192(38.9)

176(34.3)

0.314